TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Pharmacotherapy of Late-Life Mania (GERI-BD)
Brief Summary: This study will compare the benefits and side effects of lithium and divalproex in the treatment of older adults with bipolar mania.


Options:
A: Arm Label: Lithium (LI); Type: EXPERIMENTAL; Interventions: Drug: Lithium (LI) | Arm Label: Divalproex (DV); Type: EXPERIMENTAL; Interventions: Drug: Divalproex (DV) | Intervention Type: DRUG; Name: Lithium (LI); Assigned to Arm(s): Lithium (LI) | Intervention Type: DRUG; Name: Divalproex (DV); Assigned to Arm(s): Divalproex (DV)
B: Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: divalproex sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Divalproex | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Divalproex; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Lithium carbonate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Valproate | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Lithium carbonate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Valproate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial
Brief Summary: In patients with schizophrenia, 'atypical' antipsychotics such as clozapine may be effective in the treatment of psychosis. In patients with borderline personality disorder (BPD), as far as the investigators know, no well designed controlled studies have been performed on the effect of one of the newer atypical antipsychotics on psychotic symptoms.

It is of interest to investigate the benefit of quetiapine treatment in these types of patients. Quetiapine possibly gives less side-effects because of the expected lack of elevated prolactin levels, which is of importance in this patient group, overrepresented by young females. In this double blind, randomized, placebo controlled, 8 week, parallel group, multi-center study, quetiapine (in flexible doses between 200 mg/day and 600 mg/day) will be compared with the placebo.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Quetiapine fumarate | Intervention Type: DRUG; Name: Quetiapine fumarate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1
B: Arm Label: SIC + NET; Type: EXPERIMENTAL; Interventions: Behavioral: Narrative Exposure Therapy, Behavioral: Standard Inpatient Care, Other: Waiting List | Arm Label: SIC + DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy, Behavioral: Standard Inpatient Care, Other: Waiting List | Intervention Type: BEHAVIORAL; Name: Narrative Exposure Therapy; Assigned to Arm(s): SIC + NET | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): SIC + DBT | Intervention Type: BEHAVIORAL; Name: Standard Inpatient Care; Assigned to Arm(s): SIC + DBT, SIC + NET | Intervention Type: OTHER; Name: Waiting List; Assigned to Arm(s): SIC + DBT, SIC + NET
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 1, 2
D: Arm Label: General Psychiatric Management (GPM; Gunderson & Links, 2008); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychiatric Management | Arm Label: GPM plus Motive-Oriented Therapeutic Relationship; Type: EXPERIMENTAL; Interventions: Behavioral: Psychiatric Management, Behavioral: Motive-oriented therapeutic relationship/Plan Analysis | Intervention Type: BEHAVIORAL; Name: Psychiatric Management; Assigned to Arm(s): GPM plus Motive-Oriented Therapeutic Relationship, General Psychiatric Management (GPM; Gunderson & Links, 2008) | Intervention Type: BEHAVIORAL; Name: Motive-oriented therapeutic relationship/Plan Analysis; Assigned to Arm(s): GPM plus Motive-Oriented Therapeutic Relationship

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Immunogenicity of Different Multivalent Component Pertussis Vaccine Formulations Based on a 5 Component Acellular Pertussis Vaccine in Infants and Toddlers
Brief Summary: The overall aim of the study is to corroborate that a schedule consisting of 3 doses of Pentacel™ and a 4th dose of DAPTACEL® and ActHIB® or 4 doses of Pentacel™ or 4 doses of Quadracel and ActHIB® is as safe and immunogenic as a standard of care schedule based on 3 doses of the licensed-equivalent vaccines DAPTACEL®, Vero cell derived Inactivated Poliovirus vaccine (IPOL®), and ActHIB® and a 4th dose of DAPTACEL® and ActHIB®.


Options:
A: Arm Label: Study Group 1: DAPTACEL®, ActHIB®, and IPOL®; Type: EXPERIMENTAL; Interventions: Biological: DAPTACEL®. (DTaP), IPOL®., and ActHIB®. | Arm Label: Study Group 2: Pentacel®; Type: EXPERIMENTAL; Interventions: Biological: Pentacel®: DTaP-IPV/Hib combined | Arm Label: Study Group 3: DTaP-IPV and ActHIB®; Type: EXPERIMENTAL; Interventions: Biological: DTaP-IPV and ActHIB® | Arm Label: Study Group 4: Pentacel®; Type: EXPERIMENTAL; Interventions: Biological: Pentacel®: DTaP-IPV/Hib combined | Intervention Type: BIOLOGICAL; Name: DAPTACEL®. (DTaP), IPOL®., and ActHIB®.; Assigned to Arm(s): Study Group 1: DAPTACEL®, ActHIB®, and IPOL® | Intervention Type: BIOLOGICAL; Name: Pentacel®: DTaP-IPV/Hib combined; Assigned to Arm(s): Study Group 2: Pentacel® | Intervention Type: BIOLOGICAL; Name: DTaP-IPV and ActHIB®; Assigned to Arm(s): Study Group 3: DTaP-IPV and ActHIB® | Intervention Type: BIOLOGICAL; Name: Pentacel®: DTaP-IPV/Hib combined; Assigned to Arm(s): Study Group 4: Pentacel®
B: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
C: Arm Label: Group 1: Concomitant Administration; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Arm Label: Group 2: Sequential Administration; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration | Intervention Type: BIOLOGICAL; Name: NeisVac-C®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration
D: Intervention Type: BIOLOGICAL; Name: Live attenuated human rotavirus vaccine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Immunogenicity of Different Multivalent Component Pertussis Vaccine Formulations Based on a 5 Component Acellular Pertussis Vaccine in Infants and Toddlers
Brief Summary: The overall aim of the study is to corroborate that a schedule consisting of 3 doses of Pentacel™ and a 4th dose of DAPTACEL® and ActHIB® or 4 doses of Pentacel™ or 4 doses of Quadracel and ActHIB® is as safe and immunogenic as a standard of care schedule based on 3 doses of the licensed-equivalent vaccines DAPTACEL®, Vero cell derived Inactivated Poliovirus vaccine (IPOL®), and ActHIB® and a 4th dose of DAPTACEL® and ActHIB®.


Options:
A: Arm Label: Study Group 1: DAPTACEL®, ActHIB®, and IPOL®; Type: EXPERIMENTAL; Interventions: Biological: DAPTACEL®. (DTaP), IPOL®., and ActHIB®. | Arm Label: Study Group 2: Pentacel®; Type: EXPERIMENTAL; Interventions: Biological: Pentacel®: DTaP-IPV/Hib combined | Arm Label: Study Group 3: DTaP-IPV and ActHIB®; Type: EXPERIMENTAL; Interventions: Biological: DTaP-IPV and ActHIB® | Arm Label: Study Group 4: Pentacel®; Type: EXPERIMENTAL; Interventions: Biological: Pentacel®: DTaP-IPV/Hib combined | Intervention Type: BIOLOGICAL; Name: DAPTACEL®. (DTaP), IPOL®., and ActHIB®.; Assigned to Arm(s): Study Group 1: DAPTACEL®, ActHIB®, and IPOL® | Intervention Type: BIOLOGICAL; Name: Pentacel®: DTaP-IPV/Hib combined; Assigned to Arm(s): Study Group 2: Pentacel® | Intervention Type: BIOLOGICAL; Name: DTaP-IPV and ActHIB®; Assigned to Arm(s): Study Group 3: DTaP-IPV and ActHIB® | Intervention Type: BIOLOGICAL; Name: Pentacel®: DTaP-IPV/Hib combined; Assigned to Arm(s): Study Group 4: Pentacel®
B: Arm Label: rotavirus vaccine 116E 1 X 10(4); Type: EXPERIMENTAL; Interventions: Biological: Oral Rotavirus Vaccine 116E Live Attenuated | Arm Label: rotavirus vaccine 116E 1 X 10(5); Type: EXPERIMENTAL; Interventions: Biological: Oral Rotavirus Vaccine 116E Live Attenuated | Intervention Type: BIOLOGICAL; Name: Oral Rotavirus Vaccine 116E Live Attenuated; Assigned to Arm(s): rotavirus vaccine 116E 1 X 10(4), rotavirus vaccine 116E 1 X 10(5)
C: Arm Label: Rotarix + No IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine), Biological: Rotarix | Arm Label: No Rotarix + No IPV (inactivated polio vaccine); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: IPV (inactivated polio vaccine); Assigned to Arm(s): No Rotarix + IPV (inactivated polio vaccine), Rotarix + IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix + IPV (inactivated polio vaccine), Rotarix + No IPV (inactivated polio vaccine)
D: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Psychological Treatment of Separation Anxiety Disorder
Brief Summary: The purpose of this study is to determine whether a specific family based cognitive behavioral treatment program is effective in the treatment of children with separation anxiety disorder.


Options:
A: Arm Label: Social Effectiveness Therapy for Children; Type: EXPERIMENTAL; Interventions: Behavioral: Social Effectiveness Therapy for Children (SET-C) | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Pill placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pill Placebo | Intervention Type: BEHAVIORAL; Name: Social Effectiveness Therapy for Children (SET-C); Assigned to Arm(s): Social Effectiveness Therapy for Children | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Pill Placebo; Assigned to Arm(s): Pill placebo
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: family based cognitive behavior therapy | Intervention Type: BEHAVIORAL; Name: family based cognitive behavior therapy; Assigned to Arm(s): 2
C: Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Cat cognitive-behavioral therapy for anxious youth | Arm Label: Waitlist Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coping Cat cognitive-behavioral therapy for anxious youth; Assigned to Arm(s): CBT
D: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): Cognitive Behavioral Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Psychological Treatment of Separation Anxiety Disorder
Brief Summary: The purpose of this study is to determine whether a specific family based cognitive behavioral treatment program is effective in the treatment of children with separation anxiety disorder.


Options:
A: Arm Label: Cognitive-Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-Behavioral Therapy | Arm Label: Wait-list; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wait-list | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): Cognitive-Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Wait-list; Assigned to Arm(s): Wait-list
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: family based cognitive behavior therapy | Intervention Type: BEHAVIORAL; Name: family based cognitive behavior therapy; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Group CBT for children | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Group CBT for children plus parent training | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group CBT for children; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Group CBT for children plus parent training; Assigned to Arm(s): 2
D: Arm Label: 1. Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: 2. Client Centered Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Client Centered Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): 1. Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Client Centered Therapy; Assigned to Arm(s): 2. Client Centered Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Role of Soy Isoflavones in Prostate Cancer Prevention
Brief Summary: This is a randomized study evaluating the effectiveness and direct effect a commercial soy supplement has on prostate cancer and normal prostate tissue. Patient will be randomized it either receive placebo or a commercial soy supplement for 2-4 weeks prior to the planned surgery for treatment of their prostate cancer. Patient's blood and prostate tissue will be evaluated to determine the effects of the soy supplement on the prostate tissue.


Options:
A: Arm Label: Arm I: Sulfasalazine; Type: EXPERIMENTAL; Interventions: Drug: sulfasalazine | Arm Label: Arm II: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): Arm I: Sulfasalazine | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II: Placebo
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: Interferon, Retinoic Acid and radiation | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin and radiation | Intervention Type: DRUG; Name: Interferon, Retinoic Acid and radiation; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Cisplatin and radiation; Assigned to Arm(s): Group B
C: Arm Label: CIMRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: radiation therapy | Arm Label: HIMRT; Type: EXPERIMENTAL; Interventions: Radiation: radiation therapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): CIMRT, HIMRT
D: Arm Label: Arm Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Arm Soy Supplement; Type: EXPERIMENTAL; Interventions: Drug: Soy Supplement | Intervention Type: DRUG; Name: Soy Supplement; Assigned to Arm(s): Arm Soy Supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-Label Study to Assess the Long-Term Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD)
Brief Summary: The purpose of this study is to determine the long-term safety profile of daily treatment with dexlansoprazole MR in subjects with gastroesophageal reflux disease.


Options:
A: Arm Label: Esomeprazole 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Esomeprazole | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole 20 mg, Placebo
B: Arm Label: On demand 20 mg esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Continuous 20 mg esomeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Continuous 20 mg esomeprazole, On demand 20 mg esomeprazole
C: Arm Label: GERD Los Angeles A and B-4 week group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole 40 mg | Arm Label: GERD Los Angeles A and B-8-week group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole 40 mg | Intervention Type: DRUG; Name: Esomeprazole 40 mg; Assigned to Arm(s): GERD Los Angeles A and B-4 week group, GERD Los Angeles A and B-8-week group
D: Arm Label: Dexlansoprazole MR 60 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Arm Label: Dexlansoprazole MR 90 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 60 mg QD | Intervention Type: DRUG; Name: Dexlansoprazole MR; Assigned to Arm(s): Dexlansoprazole MR 90 mg QD

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Polyethylene Glycol Laxative (Macrogol 4000;Forlax®) for Treatment of Chronic Constipation in Children : A Phase III, Bicentric, Randomized, Double-blind, Lactulose Controlled Study.
Brief Summary: The purpose of this study is to determine whether Forlax® is more effective than placebo in relieving chronic constipation in children who may also suffer from soiling or faecal incontinence.


Options:
A: Arm Label: Polyethylene glycol small dose; Type: EXPERIMENTAL; Interventions: Drug: Polyethylene glycol 4000 | Arm Label: Polyethylene glycol high dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene glycol 4000 | Intervention Type: DRUG; Name: Polyethylene glycol 4000; Assigned to Arm(s): Polyethylene glycol high dose, Polyethylene glycol small dose
B: Arm Label: Macrogol (Transipeg); Type: EXPERIMENTAL; Interventions: Drug: Macrogol (Transipeg, BAY81-8430) | Arm Label: Macrogol (Forlax); Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrogol (Forlax) | Intervention Type: DRUG; Name: Macrogol (Transipeg, BAY81-8430); Assigned to Arm(s): Macrogol (Transipeg) | Intervention Type: DRUG; Name: Macrogol (Forlax); Assigned to Arm(s): Macrogol (Forlax)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PEG 4000 (Forlax®) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lactulose active and Lactulose placebo | Intervention Type: DRUG; Name: PEG 4000 (Forlax®); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Lactulose active and Lactulose placebo; Assigned to Arm(s): 2
D: Arm Label: PEG-only; Type: EXPERIMENTAL; Interventions: Device: Polyethylene glycol | Arm Label: PEG-EL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene glycol with electrolytes | Intervention Type: DRUG; Name: Polyethylene glycol with electrolytes; Assigned to Arm(s): PEG-EL | Intervention Type: DEVICE; Name: Polyethylene glycol; Assigned to Arm(s): PEG-only

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Efficacy of Milk Fortified With Bifidus DR10-Oligosaccharides, Zinc and Iron in Reducing Morbidity Due to Diarrhea, Pneumonia and Improving Growth and Development in Children Ages 13-36 Months
Brief Summary: The purpose of the study is to evaluate effect or fortifying milk with pre and probiotics or with micronutrients on prevention of diarrhea, pneumonia and other childhood illnesses and improvement in growth and development.


Options:
A: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A
B: Arm Label: Zinc gluconate; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: zinc; Assigned to Arm(s): Placebo, Zinc gluconate
C: Intervention Type: DRUG; Name: Micronutrient (Zinc and Iron) fortification; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Pre and Probiotic fortification; Assigned to Arm(s): N/A
D: Arm Label: LNS-Zn5; Type: EXPERIMENTAL; Interventions: Dietary Supplement: LNS-Zn5 | Arm Label: LNS-Zn10; Type: EXPERIMENTAL; Interventions: Dietary Supplement: LNS-Zn10 | Arm Label: LNS-Zn0; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: LNS-Zn0 | Arm Label: Suppl-Zn5; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Suppl-Zn5 | Arm Label: Delayed intervention group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Zn5; Assigned to Arm(s): LNS-Zn5 | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Zn10; Assigned to Arm(s): LNS-Zn10 | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Zn0; Assigned to Arm(s): LNS-Zn0 | Intervention Type: DIETARY_SUPPLEMENT; Name: Suppl-Zn5; Assigned to Arm(s): Suppl-Zn5

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Efficacy of Milk Fortified With Bifidus DR10-Oligosaccharides, Zinc and Iron in Reducing Morbidity Due to Diarrhea, Pneumonia and Improving Growth and Development in Children Ages 13-36 Months
Brief Summary: The purpose of the study is to evaluate effect or fortifying milk with pre and probiotics or with micronutrients on prevention of diarrhea, pneumonia and other childhood illnesses and improvement in growth and development.


Options:
A: Arm Label: Tomato Meal; Type: OTHER; Interventions: Other: Post-prandial Feeding Study | Arm Label: Carrot Meal; Type: OTHER; Interventions: Other: Post-prandial Feeding Study | Intervention Type: OTHER; Name: Post-prandial Feeding Study; Assigned to Arm(s): Carrot Meal, Tomato Meal
B: Arm Label: Fortified Yoghurt; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Fortified Yoghurt | Arm Label: Yoghurt; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Yoghurt | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Fortified Yoghurt; Assigned to Arm(s): Fortified Yoghurt | Intervention Type: DIETARY_SUPPLEMENT; Name: Yoghurt; Assigned to Arm(s): Yoghurt
C: Intervention Type: DRUG; Name: Micronutrient (Zinc and Iron) fortification; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Pre and Probiotic fortification; Assigned to Arm(s): N/A
D: Arm Label: Anemic children; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Iron, Dietary Supplement: Multiple micronutrients supplement, Dietary Supplement: micronutrient fortified porridge powder, Dietary Supplement: Iron and ascorbic acid fortified water, Dietary Supplement: Iron plus folic acid supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron; Assigned to Arm(s): Anemic children | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple micronutrients supplement; Assigned to Arm(s): Anemic children | Intervention Type: DIETARY_SUPPLEMENT; Name: micronutrient fortified porridge powder; Assigned to Arm(s): Anemic children | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron and ascorbic acid fortified water; Assigned to Arm(s): Anemic children | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron plus folic acid supplement; Assigned to Arm(s): Anemic children

Answer: C